SI-BONE, Inc.
SIBNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeSI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and. With a market capitalization of $639.1M, it sits in small-cap territory. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Market Cap
$639.1M
Beta
0.67
P/E (TTM)
—
P/E (Fwd)
-40.84
EPS (TTM)
$-0.39
EPS (Fwd)
$-0.35
ROE
-9.7%
ROA
-5.3%
Cash
$144.7M
Total Debt
$42.9M
Free CF
-$2.7M
52W Change
-23.8%
Annual Financials
Cash vs Debt
With $144.7M in cash and $42.9M in debt, SIBN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$2.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -9.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $90.2M (2021) to $200.9M (2025), reflecting a 123% increase over the period.
With a beta below 0.7, SI-BONE, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SIBN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.